Amgen Announces Appointment of Robert A. Eckert to Board of Directors

    Amgen Announces Appointment of Robert A. Eckert to Board of Directors

PR Newswire

THOUSAND OAKS, Calif., Dec. 13, 2012

THOUSAND OAKS, Calif., Dec. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN)
today announced the appointment of Robert A. Eckert, former chief executive
officer at Mattel, Inc., to its Board of Directors. Mr. Eckert will serve on
the Audit and Corporate Responsibility and Compliance Committees of the Board.
Following the appointment of Mr. Eckert and the previously announced
retirement of Kevin W. Sharer from the Board on Dec. 31, 2012, the Board on
Jan. 1, 2013, will be comprised of 14 directors, 13 of whom are independent.

"We are pleased to welcome Bob Eckert to the Amgen Board. Bob has significant
experience and a superb track record of leading global companies during a long
and successful career," said Robert A. Bradway, chief executive officer at
Amgen. "His contributions to the Board will guide us as we expand our reach to
more patients in more markets and continue creating value for our

Robert A. Eckert

Mr. Eckert, 58, currently serves as non-executive Chairman at Mattel, Inc.,
where he served as Chief Executive Officer from 2000 through 2011. Prior to
this role, Mr. Eckert was President and Chief Executive Officer of Kraft
Foods, Inc. from 1997 to 2000. Before that, Mr. Eckert served as Group Vice
President and President of Kraft's Oscar Mayer foods division. Mr. Eckert
currently serves on the Boards of Directors of McDonald's Corporation and Levi
Strauss & Co. Mr. Eckert is on the Dean's Advisory Board of the Kellogg
Graduate School of Management and serves on the Eller College of Management
National Board of Advisors at the University of Arizona. Mr. Eckert holds a
Bachelor of Arts degree from the University of Arizona and an MBA from
Northwestern University.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe and effective
medicines from lab, to manufacturing plant, to patient. Amgen therapeutics
have changed the practice of medicine, helping millions of people around the
world in the fight against cancer, kidney disease, rheumatoid arthritis, bone
disease and other serious illnesses. With a deep and broad pipeline of
potential new medicines, Amgen remains committed to advancing science to
dramatically improve people's lives. To learn more about our pioneering
science and our vital medicines, visit Follow us on

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)



Press spacebar to pause and continue. Press esc to stop.